Lts Lohmann Therapie-systeme Ag

Gruenenthal Gmbh

Grunenthal Gmbh

René Eifler

Patrick Mohr

Olga Bourquain

René Rietscher

Frank Theobald

Florian Hammes

Regine Kaufmann

Michael Horstmann

Eric Galia

Jan Stampfuss

Wolfgang Prange

Stefan Buller

Klaus Pusecker

Susanne Stoelben

The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure comprising a therapeutically effective amount of asenapine, said self-adhesive layer structure comprising: A) a backing layer; B) an asenapine-containing layer comprising: 1. asenapine in the form of the free base; and 2. a polymer selected from the group consisting of polysiloxanes and polyisobutylenes in an amount of more than 50% by weight based on the total weight of the asenapine-containing layer; and C) optionally an additional skin contact layer.

Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene

The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).

Controlling water release from a dimensionally stable aqueous composition

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

Transdermal therapeutic system containing asenapine

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising an asenapine-containing layer structure, said asenapine-containing layer structure comprising A) a backing layer and B) an asenapine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.

Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer

The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.

Transdermal administration of memantine

The present invention relates to transdermal therapeutic systems that include an occlusive back layer impervious to an active substance, a single or multilayer matrix, and a peelable protective film. The matrix or at least one of the matrix layers includes a pharmaceutical active substance or a plurality of pharmaceutical active substances in the form of at least one pharmaceutically consumable salt thereof and a pharmaceutically consumable, alkaline reacting oxide.

Transdermal therapeutic system having controlled active substance flow comprising a basic reacting oxide

The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy.

Growing community of inventors

Koblenz, Germany

René Eifler